Human Genome Sciences, Inc. (HGSI) and Morphotek(R), Inc. Partner Up to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
Today, Human Genome Sciences, Inc. and Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced together that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology, specifically targeting antigens discovered by HGS. “The rapid commercialization of our late-stage compounds continues to be the priority focus of HGS. At the same time, we also remain committed to advancing our earlier and mid-stage programs in development to ensure sustainable growth well into the future,” stated H. Thomas Watkins, President and Chief Executive Officer, HGS. “We look forward to…